THERALASE TECHNOLOGIES INC ORDINARY SHAR (OTCMKTS:TLTFF) Could Improve Your Long Portfolio After Less Shorts Reported

March 13, 2018 - By Richard Conner

The stock of THERALASE TECHNOLOGIES INC ORDINARY SHAR (OTCMKTS:TLTFF) registered a decrease of 99.82% in short interest. TLTFF’s total short interest was 100 shares in March as published by FINRA. Its down 99.82% from 55,000 shares, reported previously.

The stock decreased 0.34% or $0.001 during the last trading session, reaching $0.175. About 50,000 shares traded. Theralase Technologies Inc. (OTCMKTS:TLTFF) has 0.00% since March 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Theralase Technologies Inc. designs, develops, makes, and markets super-pulsed cold laser technology for a range of human, companion animal, and equine applications. The company has market cap of $23.32 million. The firm operates in two divisions, Therapeutic Laser Technology and Photo Dynamic Therapy. It currently has negative earnings. It engages in the production, marketing, and distribution of TLC-1000 and TLC-2000 laser technology for the treatment of nerve, muscle, tendon, ligament, joint, and wound conditions through the elimination of pain, reduction of inflammation, and acceleration of tissue healing.

More important recent Theralase Technologies Inc. (OTCMKTS:TLTFF) news were published by: which released: “Colorectal Cancer – Pipeline Review, H2 2017: 3-V Biosciences Inc, 3SBio Inc …” on January 08, 2018, also published article titled: “3 Innovative Biotech Stocks to Diversify Your Portfolio”, published: “Is a Trojan Horse the Key to Curing Cancer?” on April 12, 2017. More interesting news about Theralase Technologies Inc. (OTCMKTS:TLTFF) was released by: and their article: “Podcast: Theralase Technologies CEO on using light for pain and cancer treatment” with publication date: June 15, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: